==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 37393312 37377 10.1038/s41598-023-37377-6 Article Associations between blood inflammatory markers and bone mineral density and strength in the femoral neck: findings from the MIDUS II study Huang Zixi 4 Xu Zhenyan 2 Wan Rong 3 Hu Dongxia hudongxia5489@sina.com 1 Huang Ying hynanchang8888@163.com 1 1 grid.412455.3 0000 0004 1756 5980 Rehabilitation Department, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi China 2 grid.412455.3 0000 0004 1756 5980 Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi China 3 grid.412455.3 0000 0004 1756 5980 Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi China 4 grid.412455.3 0000 0004 1756 5980 Department of General Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi China 1 7 2023 1 7 2023 2023 13 106627 12 2022 21 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Chronic and systematic inflammation have been related to increased risks of osteopenia and related fracture. However, studies concerning the association between low-grade inflammation and the bone mineral density (BMD) and strength of the femoral neck are still few and inconsistent. This study aimed to examine the relationships between blood inflammatory biomarkers and BMD and femoral neck strength in an adult-based cohort. We retrospectively analyzed a total of 767 participants included in the Midlife in the United States (MIDUS) study. The blood levels of inflammatory markers, including interleukin-6 (IL6), soluble IL-6 receptor, IL-8, IL-10, TNF-α and C-reactive protein (CRP), in these participants were measured, and their associations with the BMD and strength of the femoral neck were determined. We analyzed these 767 subjects with data concerning the BMD, bending strength index (BSI), compressive strength index (CSI), and impact strength index (ISI) in the femoral neck and inflammatory biomarkers. Importantly, our results suggest that strongly negative associations exist between the blood soluble IL6 receptor levels and the BMD (per SD change, Sβ = −0.15; P < 0.001), CSI (per SD change, Sβ = −0.07; P = 0.039), BSI (per SD change, Sβ = −0.07; P = 0.026), and ISI (per SD change, Sβ = −0.12; P < 0.001) in the femoral neck after adjusting for age, gender, smoked cigarettes regularly, number of years drinking, BMI and regular exercise. However, the inflammatory biomarkers, including blood IL-6 (per SD change, Sβ = 0.00; P = 0.893), IL-8 (per SD change, Sβ = −0.00; P = 0.950), IL-10 (per SD change, Sβ = −0.01; P = 0.854), TNF-α (per SD change, Sβ = 0.04; P = 0.260) and CRP (per SD change, Sβ = 0.05; P = 0.137), were not strongly associated with the BMD in the femoral neck under the same conditions. Similarly, there was no significant difference in the relationships between the inflammatory biomarkers (IL-6, IL-8, IL-10, TNF-α and CRP) and the CSI, BSI, and ISI in the femoral neck. Interestingly, in concomitant inflammation-related chronic diseases, only arthritis affected the soluble IL-6 receptor and the CIS (interaction P = 0.030) and SIS (interaction P = 0.050) in the femoral neck. In this cross-sectional analysis, we only observed that high blood levels of soluble IL-6 receptor were strongly associated with reduced BMD and bone strength in the femoral neck. The independent associations between the other inflammatory indicators, including IL-6, IL-8, IL-10, TNF-α and CRP, and the BMD and femoral neck strength in an adult-based cohort were not significant. Subject terms Biochemistry Biomarkers Risk factors Jiangxi Natural Science Foundation20202BAB216009 20224BAB216019 Huang Zixi Huang Ying National Natural Science foundation of China82060049 Xu Zhenyan issue-copyright-statement© Springer Nature Limited 2023 ==== Body pmcIntroduction A progressive increase in chronic and systemic inflammatory conditions is a main characteristic of the process of aging1,2, which is accompanied by a two- to fourfold increase in the circulating levels of inflammatory biomarkers3,4, linking the process to large ranges of common health problems, including bone loss and related fractures5–7. In basic research, several studies have suggested that inflammatory cytokines can alter bone remodeling by promoting the expression of macrophage-colony stimulating factor (M-CSF) and the nuclear factor kappa B signaling pathway and inhibit osteoprotegerin production in vitro and in vivo8–13. Among clinical studies, prospective and retrospective studies have also increasingly shown that the increased circulating levels of various proinflammatory cytokines are strongly related to accelerated bone loss and a lower bone mineral density (BMD) and contribute to a higher fracture risk in older adults5,6,14,15. However, in recent years, some other clinical evidence failed to find a significant association between inflammatory cytokines and the BMD or fracture risk16–18. For example, the OsteoLaus study involving 1390 postmenopausal women reported that bone structure parameters and bone imaging are not associated with low-grade cytokine levels (within the normal range)16. The authors did not observe a relationship between prevalent or incident fractures and high-sensitivity C-reactive protein (hs-CRP) or associations between the blood interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF-α) levels and the BMD or fractures16. The Framingham Offspring Study (1996–2001) reported that the serum inflammatory biomarker concentrations, including IL-6, CRP and TNF-α, were associated with the BMD in premenopausal women but not in men. The authors finally concluded that the lack of consistency in their results suggests that elevated blood levels of inflammatory biomarkers might not be risk factors for a reduced BMD17. In addition, a longitudinal study with a mean follow-up time of 11.6 years (maximum 16.9 years) reported that CRP was not an indicator of a low BMD, bone loss, or fracture in elderly women18. These conflicting results may be related to the various health statuses, BMD positions used in the analysis and age groups in the different study populations16–18. For instance, concomitant inflammation related to pathologies or chronic diseases, such as insulin resistance, atherosclerosis, vascular disease, chronic obstructive pulmonary disease (COPD), Parkinson’s disease, dementia and others19, may be important confounders leading to inconsistent conclusions. In the present study, we sought to replicate these findings concerning the relationship between blood inflammatory biomarkers (IL-6, soluble IL-6 receptor, IL-8, IL-10, TNF-α and CRP) and the BMD and bone strength in the femoral neck using a larger and more representative sample of 1255 participants who participated in a blood biomarker project in the Midlife in the United States (MIDUS) II study. We speculated that proinflammatory cytokines, including IL-6, soluble IL-6 receptor, IL-8, TNF-α and CRP, and anti-inflammatory cytokines, including IL-10, were inversely or positively correlated with the BMD or strength of the femoral neck. By retrospectively assessing blood biomarkers, we can comprehensively and convincingly confirm these relationships. Methods Study samples We retrospectively analyzed the MIDUS study, which was conducted in 1995 and included 7108 noninstitutionalized adults, and 4,963 subjects participated in the first follow-up in MIDUS II from 2004 to 200620,21. During this follow-up period, 1255 adults participated in a biomarker project involving blood inflammation biomarkers, physical examinations and medical history data22. After each participant volunteered to visit the clinical research centers (the Georgetown University, the University of California-Los Angeles or the University of Wisconsin), trained staff or clinicians performed a fasting blood draw and a collection of medical history, and conducted a physical examination. Of the samples participating in the biomarker project (N = 1225), in total, 907 participants had complete BMD, bending strength index (BSI), compressive strength index (CSI), and impact strength index (ISI) data. After further excluding analysis variables in the present study, including blood inflammatory markers, body mass index (BMI), smoking, drinking status and concomitant diseases (N = 140), 767 study samples were finally enrolled in our study as shown in Fig. 1.Figure 1 Flow chart of the subject inclusion. Blood inflammatory biomarkers As described in the MIDUS documents from ICPSR (www.icpsr.umich.edu/web/pages/ICPSR/), fasting blood samples were collected from all participants before breakfast and then further processed and analyzed in the MIDUS Biocore Lab. The blood inflammatory biomarkers, including IL-6, IL-8, IL-10, TNF-α and CRP are described in detail in the MIDUS documents in ICPSR21,22. Assessment of BMD and bone strength in the femoral neck The BMD values of the left hip in each participant were measured by dual-energy X ray absorptiometry (DXA) scans. The femoral neck width (FNW) and femoral neck axis length (FNAL) were measured from the hip scans according to the manufacturer’s guidelines. Composite indices of the femoral neck strength, including the CSI, BSI, and ISI, were calculated. These three bone strength indices were recorded in grams per kilogram meter (g/kg m). Covariates The following covariates were included: age (years), sex (male and female), BMI, smoking status, number of drinking years, regular exercise and medical history [ever arthritis, ever transient cerebral ischemia (TIA) or stroke, ever diabetes and ever cancer]. The smoking status was defined as “whether or not ever smoked cigarettes regularly”. Regular exercise was defined as “whether or not engage in regular exercise or activity of any type for 20 min or more at least 3 times/week”. In addition to sex, all categorical variables, including the smoking status, regular exercise and medical history, were classified as “yes” or “no”. The BMI equals weight (kg) divided by the square of height (cm). Statistical analysis In the current study, the statistical analyses were conducted by EmpowerStats 3.0. A P value ≤ 0.05 was considered significant. The distributions of the variables were examined by Kolmogorov–Smirnov test. The continuous variables are expressed as the median [interquartile range (IQR)], and the categorical variables are presented as n (%). Spearman and scatter plot analyses were used to assess the association between blood inflammatory biomarkers and the BMD, CSI, BSI, and ISI of the femoral neck. Then, these continuous variables with non-normal distribution were further standardized and regression models were used to analyze the independent effect of blood inflammatory biomarkers on adverse changes in the BMD, CSI, BSI, and ISI of the femoral neck. In the calibration analysis, six types of blood inflammatory biomarkers were considered independent predictors of adverse changes in the BMD, CSI, BSI, and ISI in the femoral neck. In Model 1, each inflammatory biomarker (IL-6, soluble IL-6 receptor, IL-8, IL-10, TNF-α and CRP) was regressed on the BMD, CSI, BSI, and ISI in the femoral neck with covariates, and age and gender were adjusted. Model 2 adjusted for age, gender, ever smoked cigarettes regularly and number of drinking years. Model 3 adds BMI and regular exercise as covariates to Model 2. Specifically, subgroup analyses were further used to evaluate the effects of medical history, including ever arthritis, ever transient cerebral ischemia (TIA) or stroke, ever diabetes and ever cancer, on the relationships between the blood levels of inflammatory biomarkers and the BMD, CSI, BSI, and ISI of the femoral neck. Similar to the Model 3 analysis, age, sex, ever smoked cigarettes regularly, number of drinking years, BMI and regular exercise were adjusted in each subgroup analysis. Ethics approval and consent to participate All methods were carried out in accordance with relevant guidelines and regulations (the Declaration of Helsinki), approval from the institutional review board was obtained from each MIDUS center of the MIDUS II Biomarker Project, and all study participants provided written consent. We freely obtained these data from ICPSR (https://www.icpsr.umich.edu/web/pages/ICPSR/) where MIDUS documents is stored for free use. Results Characteristics of the participants We analyzed 767 subjects with data concerning the BMD, CSI, BSI, and ISI in the femoral neck and inflammatory biomarkers. The demographic information, including age, sex, ever smoked cigarettes regularly, number of years drinking, BMI and regular exercise, of these subjects is described in Table 1. Among these study samples, the values of the BMD, CSI, BSI, and ISI in the femoral neck were 0.89 (0.77–1.02) gms/cm2, 3.53 (3.08–4.07), 1.19 (1.03–1.37) g/kg m and 0.20 (0.17–0.23) g/kg m, respectively. The blood inflammatory markers, including IL-6, soluble IL-6 receptor, IL-8, IL-10, TNF-α and CRP, were 0.80 (0.54–1.19) pg/mL, 33,153.00 (26,479.50–41,117.00) pg/mL, 12.49 (9.38–15.83) pg/mL, 0.21 (0.16–0.31) pg/mL, 1.99 (1.63–2.39) pg/mL and 1.41 (0.68–3.37) μg/mL, respectively.Table 1 Characteristics for study subjects (n = 767). Variables N (%) or median (interquartile range) Age (year) 52 (44–60) Gender (male), n (%) 326 (42.50%) BMI (kg/m2) 28.43 (25.00–32.89) Ever smoked cigarettes regularly, n (%) 400 (52.15%) Number of years drank that much (year) 5 (2–15) regular exercise, n (%) 583 (76.01%) Medical history  Ever had arthritis, n (%) 333 (43.42%)  Ever had stroke, n (%) 28 (3.65%)  Ever had diabetes, n (%) 90 (11.73%)  Ever had cancer, n (%) 102 (13.30%) BMD and bone strength  Femoral neck BMD (g/cm2) 0.89 (0.77–1.02)  Femoral neck CSI (g/kg m) 3.53 (3.08–4.07)  Femoral neck BSI (g/kg m) 1.19 (1.03–1.37)  Femoral neck ISI (g/kg m) 0.20 (0.17–0.23) Blood inflammatory markers  IL6 (pg/mL) 0.80 (0.54–1.19)  IL8 (pg/mL) 12.49 (9.38–15.83)  IL10 (pg/mL) 0.21 (0.16–0.31)  TNF-α (pg/mL) 1.99 (1.63–2.39)  Soluble IL6 receptor (pg/mL) 33,153.00 (26,479.50–41,117.00)  CRP (μg/mL) 1.41 (0.68–3.37) BMI body mass index, BMD bone mineral density, CSI compression strength index, BSI bending strength index, ISI impact strength index, MSD meso scale discovery, IL interleukin, TNF-α tumor necrosis factor-α, CRP C-reactive protein. Relationships between blood inflammatory biomarkers and the BMD and bone strength (CSI, BSI, and ISI) in the femoral neck As shown in Supplementary materials 1, Spearman’s methods demonstrated that the blood levels of IL-6, soluble IL-6 receptor and CRP, but not those of IL-8, IL-10 and TNF-α, are inversely related to the BMD, CSI, BSI and ISI in the femoral neck (all P < 0.05). The scatter plot analysis suggested that the elevated blood levels of soluble IL-6 receptor were closely associated with reduced values of the BMD, CSI, BSI and ISI (Fig. 2, all < 0.05).Figure 2 Scatter diagram of the associations between the blood soluble IL-6 receptor levels and lower BMD and bone strength. As shown in Table 2, Model 1 suggested that significant inverse associations exist between the blood soluble IL-6 receptor levels and the BMD (per SD change, Sβ = − 0.15; 95% CI −0.22, −0.08; P < 0.001), CSI (per SD change, Sβ = −0.08; 95% CI −0.15, −0.01; P = 0.029), BSI (per SD change, Sβ = −0.07; 95% CI −0.14, −0.01; P = 0.035), and ISI (per SD change, Sβ = −0.13; 95% CI -0.20, -0.06; P < 0.001) in the femoral neck after controlling for age and sex. Importantly, Model 3 still suggested that strong negative associations exist between the blood soluble IL-6 receptor levels and the BMD (per SD change, Sβ = −0.15; 95% CI −0.22, −0.09; P < 0.001), CSI (per SD change, Sβ = −0.07; 95% CI −0.13, 0.00); P = 0.039), BSI (per SD change, Sβ = −0.07; 95% CI −0.13, −0.01; P = 0.026), and ISI (per SD change, Sβ = −0.12; 95% CI −0.18, −0.06; P < 0.001) in the femoral neck after further adjusting for smoked cigarettes regularly; the number of years drinking, BMI and regular exercise. However, our results did not show that inflammatory biomarkers, including blood IL-6 (per SD change, Sβ = 0.00; 95% CI -0.06, 0.07; P = 0.893), IL-8 (per SD change, Sβ = −0.00; 95% CI −0.06, 0.06; P = 0.950), IL-10 (per SD change, Sβ = −0.01; 95% CI −0.07, 0.06; P = 0.854), TNF-α (per SD change, Sβ = 0.04; 95% CI −0.03, 0.10; P = 0.260) and CRP (per SD change, Sβ = 0.05; 95% CI −0.02, 0.12; P = 0.137), were strongly associated with the BMD in the femoral neck after controlling for age, sex, ever smoked cigarettes regularly, number of years drinking, BMI and regular exercise. Similarly, there was no significant difference in the relationships between the inflammatory biomarkers (IL-6, IL-8, IL-10, TNF-α and CRP) and the CSI, BSI, and ISI in the femoral neck.Table 2 Linear regression analysis for relationships between blood inflammatory markers level and BMD and bone strength in femoral neck. Variables Model 1 Model 2 Model 3 Per SD change (95% CI) P value Per SD change (95% CI) P value Per SD change (95% CI) P value Femoral neck BMD (g/cm2)  IL6 (pg/mL) 0.04 (−0.03, 0.11) 0.233 0.04 (−0.03, 0.10) 0.272 0.00 (−0.06, 0.07) 0.893  IL8 (pg/mL) −0.02 (−0.08, 0.05) 0.659 −0.02 (−0.09, 0.05) 0.563 −0.00 (−0.06, 0.06) 0.950  IL10 (pg/mL) −0.01 (−0.08, 0.05) 0.705 −0.01 (−0.08, 0.06) 0.733 −0.01 (−0.07, 0.06) 0.854  TNF-α (pg/mL) 0.08 (0.01, 0.15) 0.025 0.08 (0.01, 0.15) 0.024 0.04 (−0.03, 0.10) 0.260  Soluble IL6 receptor (pg/mL) −0.15 (−0.22, −0.08)  < 0.001 −0.14 (−0.21, −0.08)  < 0.001 −0.15 (−0.21, −0.09)  < 0.001  CRP (μg/mL) 0.17 (0.11, 0.24)  < 0.001 0.17 (0.11, 0.24)  < 0.001 0.05 (−0.02, 0.12) 0.137 CSI (g/kg m)  IL6 (pg/mL) −0.05 (−0.12, 0.02) 0.166 −0.05 (−0.13, 0.02) 0.129 −0.01 (−0.08, 0.05) 0.654  IL8 (pg/mL) 0.03 (−0.04, 0.10) 0.459 0.02 (−0.05, 0.09) 0.558 −0.00 (−0.06, 0.06) 0.969  IL10 (pg/mL) −0.01 (−0.08, 0.06) 0.776 −0.01 (−0.08, 0.06) 0.815 −0.02 (−0.08, 0.05) 0.638  TNF-α (pg/mL) −0.04 (−0.12, 0.03) 0.232 −0.04 (−0.12, 0.03) 0.232 0.01 (−0.06, 0.07) 0.810  Soluble IL6 receptor (pg/mL) −0.08 (−0.15, −0.01) 0.029 −0.07 (−0.14, 0.00) 0.050 −0.07 (−0.13, 0.00) 0.039  CRP (μg/mL) −0.13 (−0.21, −0.06)  < 0.001 −0.13 (−0.21, −0.06)  < 0.001 0.02 (−0.05, 0.09) 0.570 BSI (g/kg m)  IL6 (pg/mL) −0.04 (−0.11, 0.03) 0.295 −0.04 (−0.11, 0.03) 0.286 0.01 (−0.06, 0.07) 0.869  IL8 (pg/mL) 0.01 (−0.06, 0.08) 0.730 0.01 (−0.06, 0.08) 0.797 −0.01 (−0.08, 0.05) 0.633  IL10 (pg/mL) −0.01 (−0.08, 0.06) 0.859 −0.01 (−0.08, 0.06) 0.848 −0.01 (−0.08, 0.05) 0.653  TNF-α (pg/mL) −0.04 (−0.11, 0.03) 0.260 −0.04 (−0.11, 0.03) 0.263 0.01 (−0.05, 0.08) 0.640  Soluble IL6 receptor (pg/mL) −0.07 (−0.14, −0.01) 0.035 −0.07 (−0.14, −0.00) 0.040 −0.07 (−0.13, −0.01) 0.026  CRP (μg/mL) −0.14 (−0.21, −0.07)  < 0.001 −0.14 (−0.21, −0.07)  < 0.001 0.03 (−0.04, 0.09) 0.376 ISI (g/kg m)  IL6 (pg/mL) −0.07 (−0.14, −0.00) 0.045 −0.07 (−0.14, −0.00) 0.038 −0.02 (−0.08, 0.03) 0.410  IL8 (pg/mL) 0.04 (−0.03, 0.11) 0.296 0.03 (−0.04, 0.10) 0.367 0.00 (−0.05, 0.06) 0.866  IL10 (pg/mL) −0.01 (−0.08, 0.06) 0.722 −0.01 (−0.08, 0.06) 0.727 −0.02 (−0.08, 0.04) 0.477  TNF-α (pg/mL) −0.04 (−0.11, 0.03) 0.286 −0.04 (−0.11, 0.03) 0.289 0.03 (−0.03, 0.08) 0.397  Soluble IL6 receptor (pg/mL) −0.13 (−0.20, −0.06)  < 0.001 −0.13 (−0.20, −0.06)  < 0.001 −0.12 (−0.18, −0.06)  < 0.001  CRP (μg/mL) −0.16 (−0.23, −0.09)  < 0.001 −0.16 (−0.23, −0.09)  < 0.001 0.03 (−0.03, 0.10) 0.272 Model 1: adjusted for age and gender. Model 2: adjusted for age, gender, ever smoked cigarettes regularly and number of years drank that much. Model 3: adjusted for age, gender, ever smoked cigarettes regularly, number of years drank that much, BMI and regular exercise. BMD bone mineral density, CSI compression strength index, BSI bending strength index, ISI impact strength index, IL interleukin, TNF tumor necrosis factor, CRP C-reactive protein, BMI body mass index. Arthritis differences in the associations between the soluble IL-6 receptor and bone strength in the femoral neck Concomitant inflammation-related chronic diseases, such as cancer, vascular disease, diabetes and arthritis, have been confirmed to be associated with systemic inflammation in the body19. Our subgroup analysis showed that arthritis can affect the associations between the soluble IL-6 receptor and the CIS (interaction P = 0.030) and ISI (interaction P = 0.050) in the femoral neck. The elevated soluble IL-6 receptor levels were independently and negatively associated with a reduced CIS and ISI in the subjects (all P < 0.05) without arthritis but not in those with arthritis (all P > 0.05; Table 3). However, “ever had transient cerebral ischemia (TIA) or stroke”, “ever had diabetes” and “ever had cancer”, as well as gender and BMI (Supplementary materials 1), did not affect the relationships between the blood levels of inflammatory biomarkers and the BMD (all interaction P >0.05), CSI (all interaction P > 0.05), BSI (all interaction P > 0.05), and ISI (all interaction P > 0.05) in the femoral neck.Table 3 Subgroup analysis based medical history for relationships between blood soluble IL6 receptor levels and BMD and bone strength in femoral neck. Variables Per SD change (95% CI) P value Interaction P Femoral neck BMD (g/cm2)  Ever had arthritis −0.12 (−0.21, −0.03) 0.008 0.348  NO −0.18 (−0.26, −0.09)  < 0.001  Ever had stroke −0.08 (−0.46, 0.30) 0.696 0.726  NO −0.15 (−0.22, −0.09)  < 0.001  Ever had diabetes −0.18 (−0.37, 0.00) 0.058 0.525  NO −0.14 (−0.20, −0.07)  < 0.001  Ever had cancer −0.04 (−0.22, 0.15) 0.699 0.199  NO −0.16 (−0.23, −0.09)  < 0.001 CSI (g/kg m)  Ever had arthritis 0.01 (−0.08, 0.09) 0.911 0.030  NO −0.13 (−0.22, −0.05) 0.003  Ever had stroke −0.18 (−0.63, 0.28) 0.454 0.638  NO −0.07 (−0.13, −0.01) 0.035  Ever had diabetes −0.14 (−0.32, 0.03) 0.108 0.409  NO −0.06 (−0.13, 0.01) 0.098  Ever had cancer −0.03 (−0.19, 0.13) 0.735 0.654  NO −0.07 (−0.14, −0.00) 0.042 BSI (g/kg m)  Ever had arthritis −0.03 (−0.13, 0.06) 0.479 0.236  NO −0.11 (−0.19, −0.03) 0.008  Ever had stroke −0.34 (−1.12, 0.43) 0.394 0.206  NO −0.07 (−0.13, −0.01) 0.019  Ever had diabetes −0.11 (−0.27, 0.05) 0.184 0.728  NO −0.07 (−0.14, −0.00) 0.037  Ever had cancer −0.01 (−0.22, 0.20) 0.913 0.458  NO −0.08 (−0.15, −0.02) 0.011 ISI (g/kg m)  Ever had arthritis −0.07 (−0.16, 0.02) 0.117 0.050  NO −0.17 (−0.25, −0.10)  < 0.001  Ever had stroke −0.15 (−0.72, 0.42) 0.615 0.915  NO −0.13 (−0.18, −0.07)  < 0.001  Ever had diabetes −0.15 (−0.31, 0.02) 0.087 0.828  NO −0.12 (−0.19, −0.06)  < 0.001  Ever had cancer −0.03 (−0.22, 0.16) 0.790 0.212  NO −0.14 (−0.20, −0.08) Adjusted for age, gender, ever smoked cigarettes regularly, number of years drank that much, BMI and regular exercise. BMD bone mineral density, CSI compression strength index, BSI bending strength index, ISI impact strength index, IL interleukin. Discussion Using data from the MIDUS II study, which included a cohort of 1,255 noninstitutionalized adults, we verified the associations between blood inflammatory biomarker levels and the BMD and bone strength (CSI, BSI and ISI) in the femoral neck. Higher blood soluble IL-6 receptor levels were associated with a lower BMD and bone strength in the femoral neck. The fully adjusted relationship was slightly altered after adjusting for many covariates (age, sex, ever smoked cigarettes regularly, number of years drinking, BMI and regular exercise). There were no significant differences between blood inflammatory biomarkers (IL-6, IL-8, IL-10 and TNF-α) and the BMD and bone strength in the femoral neck. Immune inflammatory reactions change across the course of life, which has been considered attributable to overloading the immune system in response to persistent low-grade inflammation and stress24,25. Existing evidence has demonstrated that low-level inflammation tends to cause DNA damage, cellular senescence and biological aging. Studies have even demonstrated the promotional effect of proinflammatory cytokines, including IL-1β, IL-6 and TNF-α, in altering bone structure26 by inhibiting the activation and proliferation of osteoblasts. From a clinical perspective, previous studies have also reported various associations between IL-6, IL-8, IL-10, CRP and TNF-α and BMD and fracture risk27. Relationship between blood CRP levels and the BMD and bone strength of the femoral neck CRP is a very sensitive and widely studied inflammatory marker. Some investigations have suggested that high hs-CRP is linked to increased risks of a lower BMD and fracture28–30. The Geelong Osteoporosis study reported that as CRP increased with each SD, fracture risk was significantly and independently increased by 24–32%29. The Rotterdam study suggested that hs-CRP was related to an increased risk of incident fracture, but this relationship was statistically significant only in females31. Consistently, our results also demonstrated that higher CRP levels were related to lower BMD and bone strength in the femoral neck, and this relationship was dependent on age, sex, ever smoked cigarettes regularly and number of years drinking. However, some other studies were unable to find significant relationships29,31,32. Interestingly, continued adjustment for BMI and regular exercise completely eliminated this independent association in our study. Here, we observed that the demographic characteristics, lifestyle and disease history of the study sample may be important confounding factors, resulting in differences in numerous previous studies. Association between the blood soluble IL-6 receptor levels and the BMD and bone strength of the femoral neck IL-6, characterized as a cytokine with multiple functions, plays an important role in regulating immunologic and inflammatory responses in vivo and is involved in regulating bone resorption and osteoclastogenesis in some pathological conditions. IL-6 can play a biological role by binding a signal transducing receptor (gp130) and soluble receptor (sIL-6R)33. Interestingly, the existing evidence concerning IL-6 is also controversial. On the one hand, a previous study reported that higher blood IL-6 levels were positively related to a reduced BMD6. On the other hand, Cauley et al. also observed elevated IL-6 levels in males, but not in females, who experienced hip fractures14,34, which is not consistent with our results that higher blood soluble IL-6 receptor, but not blood IL-6 levels, were related to lower BMD and bone strength in the femoral neck after fully adjusting for covariates. In addition to the different results caused by the confounding factors described above, the measurement repeatability of blood IL-6 is relatively difficult, which could partly explain the discrepancies in the previous literature. Furthermore, regarding the pathological mechanism, blood IL-6 is the only cell factor with daily fluctuation, and its levels were at the lowest point in the morning35. Thus, the time of blood drawing may also be a factor leading to differences among these research conclusions. However, a recent study also surprisingly concluded that only blood sIL-6R, but not IL-6, was a significant biomarker associated with BMD changes in postmenopausal women33, and these results are similar to our study. The unique difference was that our results did not show a significant sex difference in the independent association. Relationships between the blood TNF-α levels and the BMD and bone strength of the femoral neck TNF-α, which originates from activated macrophages, is also an important cytokine for regulating bone resorption and osteoclastogenesis when inflammation occurs in vitro and in vivo. The Health Aging and Body Composition Study involving thousands of individuals (> 70 years) demonstrated that the fracture incidence was significantly elevated with elevated TNF-α levels14. However, chronic inflammatory diseases were not assessed in the patients, and the results were not adjusted for lifestyle factors, such as BMI and regular exercise. Inconsistently, there was no significant difference in the relationships between TNF-α and bone strength (CSI, BSI, and ISI) in the femoral neck in our study, even if it was only adjusted for age and sex. The short half-life of blood TNF-α concentrations may partly explain the discrepancy because elevated TNF-α levels are usually transient14. Therefore, the time point of blood measurement may also be an important confounding factor responsible for the discrepancy. Relationships between the blood IL-8 levels and the BMD and bone strength of the femoral neck IL-8, a cytokine belonging to the chemokine family, has a cellular chemotactic effect on neutrophils to regulate their inflammatory response. A previous study reported an association between elevated IL-8 and an increased decline of the lumbar spine36, which is consistent with the adverse effects of inflammatory responses on the BMD. However, this conclusion was unreliable because there was not analysis in the fully adjusted model. In our study, we did not confirm that an independent association exists between the blood levels of IL-18 and the BMD and bone strength in the femoral neck after adequately controlling for confounding factors, including age, sex, ever smoked cigarettes regularly, number of years drinking, BMI and regular exercise. Relationships between the blood IL-10 levels and the BMD and bone strength of the femoral neck As an anti-inflammatory cytokine, IL-10 can dampen immune activation stimulated by lipopolysaccharide and T helper 1-cell activity. Experiments have shown that IL-10 deficiency can cause adverse outcomes in bone, such as attenuating bone formation and progressing osteopenia in animal models37. A previous human study also supported the cellular effect based on findings suggesting that higher variants of IL-10 was associated with a reduced BMD in postmenopausal females38. Inconsistently, in the present study, we also identified associations between the blood levels of IL-10 and the BMD and bone strength in the femoral neck, reporting no significant differences, even if no confounding factor was adjusted. Strengths and limitations Currently, to the best of our knowledge, this study represents the first clinical exploration of the associations between bone parameters (BMD, CSI, BSI, and ISI) in the femoral neck and inflammatory biomarkers (IL-6, soluble IL-6 receptor, IL-8, IL-10, CRP and TNF-α) within the normal range among large population-based noninstitutionalized adults. We observed for the first time that higher soluble blood IL-6 receptor levels were associated with an increased risk of bone loss (reduced BMD) and decreased bone strength (reduced CSI, BSI, and ISI) in the femoral neck. Importantly, we should also emphasize several limitations. First, we retrospectively conducted a cross-sectional analysis, and circulating inflammatory cytokines were measured once during a certain period. Data concerning the dynamic changes in blood inflammatory cytokines are not available. Additionally, the highest inflammatory mediator concentrations should appear in the bone marrow microenvironment rather than circulating blood. Second, although age, sex, ever smoked cigarettes regularly, number of years drinking, BMI and regular exercise were adjusted in our study, medication use such as steroid and non-steroidal anti-inflammatory drugs, calcium carbonate and others was not analyzed in our study, which may affect the stability of our results to some extent. Third, we only measured sIL-6R, which is more stable than IL-6, and we did not measure the receptor levels of the other inflammatory factors. We still do not know why we only observed an association of IL-6 receptor levels, but not the other inflammatory markers, with bone health parameters, which needs research evidence in the future. Fourth, the medical history (ever arthritis, ever TIA or stroke, ever diabetes and ever cancer) used was derived from the participants' self-reports; thus, the precise medical history of these subjects was unknown, potentially impacting the results. Fifth, only 767 study subjects were enrolled from the biomarker project of the MIDUS II study. The remaining subjects with incomplete data were not analyzed in our study (N = 488). Additionally, there are no variables such as race, lumbar BMD included in this study, which may slightly hinder the external implementation of the conclusions. Conclusions We observed significant associations between the blood soluble IL-6 receptor, but not the other inflammatory biomarkers (IL-6, IL-8, IL-10, CRP and TNF-α), and the BMD and bone strength of the femoral neck, adding new evidence to the previous theory that femoral neck health can be influenced by the inflammatory phenotype. Supplementary Information Supplementary Information. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-023-37377-6. Author contributions Z.H. and Z.X. wrote the main manuscript text; R.W. completed the validation; D.H. and Y.H. supervised and revised this the manuscrip. All authors reviewed the manuscript. Funding The study is supported by Jiangxi Provincial Natural Science Foundation [20224BAB216019], Jiangxi Natural Science Foundation [20202BAB216009] and National Natural Science Foundation of China [82060049]. Data availability The datasets generated and/or analysed during the current study are available in the [ICPSR] repository (https://www.icpsr.umich.edu/web/pages/ICPSR/). Competing interests The authors declare no competing interests. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Zixi Huang and Zhenyan Xu. ==== Refs References 1. Ambrosi TH Marecic O McArdle A Sinha R Gulati GS Tong X Wang Y Steininger HM Hoover MY Koepke LS Murphy MP Sokol J Seo EY Tevlin R Lopez M Brewer RE Mascharak S Lu L Ajanaku O Conley SD Seita J Morri M Neff NF Sahoo D Yang F Weissman IL Longaker MT Chan CKF Aged skeletal stem cells generate an inflammatory degenerative niche Nature 2021 597 7875 256 262 10.1038/s41586-021-03795-7 34381212 2. Liberale L Badimon L Montecucco F Lüscher TF Libby P Camici GG Inflammation, aging, and cardiovascular disease: JACC review topic of the week J. Am. Coll. Cardiol. 2022 79 8 837 847 10.1016/j.jacc.2021 35210039 3. Ballou SP Lozanski FB Hodder S Rzewnicki DL Mion LC Sipe JD Ford AB Kushner I Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons Age Ageing 1996 25 3 224 230 10.1093/ageing/25.3.224 8670558 4. Brüünsgaard H Pedersen BK Age-related inflammatory cytokines and disease Immunol. Allergy Clin. N. Am. 2003 23 1 15 39 10.1016/s0889-8561(02)00056-5 5. Koh JM Khang YH Jung CH Bae S Kim DJ Chung YE Kim GS Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: Evidence for a link between systemic inflammation and osteoporosis Osteoporos Int. 2005 16 10 1263 1271 10.1007/s00198-005-1840-5 15702263 6. Ding C Parameswaran V Udayan R Burgess J Jones G Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: A longitudinal study J. Clin. Endocrinol. Metab. 2008 93 5 1952 1958 10.1210/jc.2007-2325 18285417 7. Josephson AM Bradaschia-Correa V Lee S Leclerc K Patel KS Muinos Lopez E Litwa HP Neibart SS Kadiyala M Wong MZ Mizrahi MM Yim NL Ramme AJ Egol KA Leucht P Age-related inflammation triggers skeletal stem/progenitor cell dysfunction Proc. Natl. Acad. Sci. USA 2019 116 14 6995 7004 10.1073/pnas.1810692116 30894483 8. Clowes JA Riggs BL Khosla S The role of the immune system in the pathophysiology of osteoporosis Immunol. Rev. 2005 208 207 227 10.1111/j.0105-2896.2005.00334.x 16313351 9. Manolagas SC Jilka RL Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis N. Engl. J. Med. 1995 332 5 305 311 10.1056/NEJM199502023320506 7816067 10. Abu-Amer Y Erdmann J Alexopoulou L Kollias G Ross FP Teitelbaum SL Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis J. Biol. Chem. 2000 275 35 27307 27310 10.1074/jbc.M003886200 10874036 11. Bertolini DR Nedwin GE Bringman TS Smith DD Mundy GR Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors Nature 1986 319 6053 516 518 10.1038/319516a0 3511389 12. Jilka RL Hangoc G Girasole G Passeri G Williams DC Abrams JS Boyce B Broxmeyer H Manolagas SC Increased osteoclast development after estrogen loss: Mediation by interleukin-6 Science 1992 257 5066 88 91 10.1126/science.1621100 1621100 13. Poli V Balena R Fattori E Markatos A Yamamoto M Tanaka H Ciliberto G Rodan GA Costantini F Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion EMBO J. 1994 13 5 1189 1196 10.1002/j.1460-2075.1994.tb06368.x 8131749 14. Cauley JA Danielson ME Boudreau RM Forrest KY Zmuda JM Pahor M Tylavsky FA Cummings SR Harris TB Newman AB Health ABC Study. Inflammatory markers and incident fracture risk in older men and women: The Health Aging and Body Composition Study J. Bone Miner. Res. 2007 22 7 1088 1095 10.1359/jbmr.070409 17419681 15. Ishii S Cauley JA Greendale GA Crandall CJ Danielson ME Ouchi Y Karlamangla AS C-reactive protein, bone strength, and nine-year fracture risk: Data from the Study of Women's Health Across the Nation (SWAN) J. Bone Miner. Res. 2013 28 7 1688 1698 10.1002/jbmr.1915 23456822 16. Fischer J Hans D Lamy O Marques-Vidal P Vollenweider P Aubry-Rozier B "Inflammaging" and bone in the OsteoLaus cohort Immun. Ageing 2020 5 17 5 10.1186/s12979-020-00177-x 17. Sponholtz TR Zhang X Fontes JD Meigs JB Cupples LA Kiel DP Hannan MT McLean RR Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women Arthritis Care Res. (Hoboken) 2014 66 8 1233 1240 10.1002/acr.22270 24375982 18. Berglundh S Malmgren L Luthman H McGuigan F Åkesson K C-reactive protein, bone loss, fracture, and mortality in elderly women: A longitudinal study in the OPRA cohort Osteoporos. Int. 2015 26 2 727 735 10.1007/s00198-014-2951-7 25410434 19. Redlich K Smolen JS Inflammatory bone loss: Pathogenesis and therapeutic intervention Nat. Rev. Drug Discov. 2012 11 3 234 250 10.1038/nrd3669 22378270 20. Brim OG Baltes PB Bumpass LL Cleary PD Featherman DL Hazzard WR Kessler RC Lachman ME Markus HR Marmot MG Rossi AS Ryff CD Shweder RA 2019 Midlife in the United States (MIDUS 1), 1995–1996 (ICPSR 2760; Version V18) ICPSR 10.3886/ICPSR02760.v18 21. Ryff CD Seeman T Weinstein M 2019 Midlife in the United States (MIDUS 2): Biomarker Project, 2004–2009 (ICPSR 29282; Version V9) ICPSR 10.3886/ICPSR29282.v9 22. Ryff C Almeida DM Ayanian J Carr DS Cleary PD Coe C Davidson R Krueger RF Lachman ME Marks NF Mroczek DK Seeman T Seltzer MM Singer BH Sloan RP Tun PA Weinstein M Williams D 2017 Midlife in the United States (MIDUS 2), 2004–2006 (ICPSR 4652; Version V7) ICPSR 10.3886/ICPSR04652.v7 23. Karlamangla AS Barrett-Connor E Young J Greendale GA Hip fracture risk assessment using composite indices of femoral neck strength: The Rancho Bernardo study Osteoporos. Int. 2004 15 1 62 70 10.1007/s00198-003-1513-1 14605798 24. Gerli R Monti D Bistoni O Mazzone AM Peri G Cossarizza A Di Gioacchino M Cesarotti ME Doni A Mantovani A Franceschi C Paganelli R Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians Mech. Ageing Dev. 2000 121 1–3 37 46 10.1016/s0047-6374(00)00195-0 11164458 25. Fulop T Larbi A Dupuis G Le Page A Frost EH Cohen AA Witkowski JM Franceschi C Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes? Front. Immunol. 2018 10 8 1960 10.3389/fimmu.2017.01960 26. Boyle WJ Simonet WS Lacey DL Osteoclast differentiation and activation Nature 2003 423 6937 337 342 10.1038/nature01658 12748652 27. Santiprabhob J Charoentawornpanich P Khemaprasit K Manpayak T Kiattisakthavee P Pipatsathian A Wannasilp N Tangjittipokin W Effect of gender, diabetes duration, inflammatory cytokines, and vitamin D level on bone mineral density among Thai children and adolescents with type 1 diabetes Bone 2021 153 116112 10.1016/j.bone.2021.116112 34252600 28. Boutroy S Hans D Sornay-Rendu E Vilayphiou N Winzenrieth R Chapurlat R Trabecular bone score improves fracture risk prediction in non-osteoporotic women: The OFELY study Osteoporos. Int. 2013 24 1 77 85 10.1007/s00198-012-2188-2 23070481 29. Pasco JA Kotowicz MA Henry MJ Nicholson GC Spilsbury HJ Box JD Schneider HG High-sensitivity C-reactive protein and fracture risk in elderly women JAMA 2006 296 11 1353 1355 10.1001/jama.296.11.1353 16985226 30. Barbour KE Boudreau R Danielson ME Youk AO Wactawski-Wende J Greep NC LaCroix AZ Jackson RD Wallace RB Bauer DC Allison MA Cauley JA Inflammatory markers and the risk of hip fracture: The Women's Health Initiative J. Bone Miner. Res. 2012 27 5 1167 1176 10.1002/jbmr.1559 22392817 31. Oei L Campos-Obando N Dehghan A Oei EH Stolk L van Meurs JB Hofman A Uitterlinden AG Franco OH Zillikens MC Rivadeneira F Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: The Rotterdam Study Osteoporos. Int. 2014 25 4 1247 1254 10.1007/s00198-013-2578-0 24337661 32. Ilesanmi-Oyelere BL Schollum L Kuhn-Sherlock B McConnell M Mros S Coad J Roy NC Kruger MC Inflammatory markers and bone health in postmenopausal women: A cross-sectional overview Immun. Ageing 2019 10 16 15 10.1186/s12979-019-0155-x 33. Giuliani N Sansoni P Girasole G Vescovini R Passeri G Passeri M Pedrazzoni M Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes Exp. Gerontol. 2001 36 3 547 557 10.1016/s0531-5565(00)00220-5 11250125 34. Cauley JA Barbour KE Harrison SL Cloonan YK Danielson ME Ensrud KE Fink HA Orwoll ES Boudreau R Inflammatory markers and the risk of hip and vertebral fractures in men: The osteoporotic fractures in men (MrOS) J. Bone Miner. Res. 2016 31 12 2129 2138 10.1002/jbmr.2905 27371811 35. Nilsonne G Lekander M Åkerstedt T Axelsson J Ingre M Diurnal variation of circulating interleukin-6 in humans: A meta-analysis PLoS ONE 2016 11 11 e0165799 10.1371/journal.pone.0165799 27832117 36. Fuggle NR Westbury LD Syddall HE Duggal NA Shaw SC Maslin K Dennison EM Lord J Cooper C Relationships between markers of inflammation and bone density: Findings from the Hertfordshire Cohort Study Osteoporos. Int. 2018 29 7 1581 1589 10.1007/s00198-018-4503-z 29808230 37. Dresner-Pollak R Gelb N Rachmilewitz D Karmeli F Weinreb M Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones Gastroenterology 2004 127 3 792 801 10.1053/j.gastro.2004.06.013 15362035 38. Park BL Han IK Lee HS Kim LH Kim SJ Shin JS Kim SY Shin HD Association of interleukin 10 haplotype with low bone mineral density in Korean postmenopausal women J. Biochem. Mol. Biol. 2004 37 6 691 699 10.5483/bmbrep.2004.37.6.691 15607028